Xvivo Perfusion AB
The answer first
Does Xvivo Perfusion beat the market?
Yes, Xvivo Perfusion has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 30% of Nordic stocks
- Quality73
- Value18
- Trend34
No. 104 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Xvivo Perfusion keeps must grow about 9% a year for 10 years.
Max for seven days
Follow Xvivo Perfusion with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 20 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Xvivo Perfusion
Your first answer is free, no account needed.
Do you own Xvivo Perfusion, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Xvivo Perfusion and a few more. Free, no card.
Super Stock+45.4%In short
- Xvivo Perfusion has risen 18.4% over the past year, including dividends.
- Overall, Xvivo Perfusion ranks better than 30% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 70.2%. The price is 63.6% below its peak now.
What do analysts think of Xvivo Perfusion?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 30% of Nordic stocks.
No. 104 of 195 in healthcare
High A solid company: it earns well on its money and has healthy finances.
No. 75 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.11
- Asset turnoverSales divided by everything the company owns0.37
- Return on equityProfit divided by equity+5.7%
- Cash conversionOperating cash flow divided by profit2.09
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 104 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity2.7
- P/SPrice divided by sales6.3
- P/EPrice divided by earnings47.0
- P/CFPrice divided by operating cash flow22.5
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 98 of 198 in healthcareTypical in healthcare: 33Typical in the Nordics: 50
- 3 months−29.7%
- 6 months−32.0%
- 9 months+9.1%
- 12 months+18.4%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Xvivo Perfusion
22 funds we follow own Xvivo Perfusion. The share is how much of the fund the stock makes up.
- Norway1
- Sweden21
- 1 ETF
- Lannebo Hälsa och Ny Teknik ASweden · Lannebo5.5%
- TIN Ny Teknik FSweden · TIN5.5%
- Case Gaia MicrocapSweden · Case2.5%
- PLUS Hälsovård Sverige IndexSweden · PLUS2.4%
- Skandia Småbolag SverigeSweden · Skandia1.0%
- Öhman Sweden Micro Cap ASweden · Öhman0.8%
- Xact Svenska Småbolag (UCITS ETF)Sweden · XACT · ETF0.3%
- Skandia Småbolag Sverige Exponering ASweden · Skandia0.3%
Show all 22
- Handelsbanken Nordiska Småbol (A1 NOK)Sweden · Handelsbanken0.2%
- PLUS Småbolag Sverige IndexSweden · PLUS0.2%
- Folksam LO SverigeSweden · Folksam0.2%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.2%
- Skandia Sverige ExponeringSweden · Skandia0.1%
- Nordea Småbolagsfond SverigeSweden · Nordea0.1%
- Öhman Etisk Index Sverige ASweden · Öhman0.1%
- PLUS Allabolag Sverige IndexSweden · PLUS0.1%
- Skandia Världen SverigeSweden · Skandia0.1%
- KLP AksjeNorden IndeksNorway · KLP0.0%
- Skandia SMART FörsiktigSweden · Skandia0.0%
- GodFond Sverige & VärldenSweden · GodFond0.0%
- Handelsbanken Gl Småbolag I Crit A9 EURSweden · Handelsbanken0.0%
- Handelsbanken Gl Småbolag Ind Cri A1 NOKSweden · Handelsbanken0.0%
From the funds' latest known holdings.
About Xvivo Perfusion
Xvivo Perfusion AB is a company in healthcare, listed on Nasdaq Stockholm. By market value, Xvivo Perfusion is number 23 of 137 companies in healthcare on Nasdaq Stockholm. Xvivo Perfusion has not paid a dividend in the past twelve months. Of the three measures in the ranking, Xvivo Perfusion is strongest on quality, better than 73% of Nordic stocks. The next report from Xvivo Perfusion is expected on 28 January 2027. The share trades in SEK. It has around 210 employees.
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entir…


See the full analysis of Xvivo Perfusion.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card